Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Laura Tucker; Alexander Allen; David Chandler; Coziana Ciurtin; Andrew Dick; Amy Foulkes; Nicola Gullick; Philip Helliwell; Deepak Jadon; Gareth Jones; Stuart Kyle; Vishnu Madhok; Neil McHugh; Andrew Parkinson; Tim Raine; Stefan Siebert; Catherine Smith; William Tillett; Laura C. Coates

doi:10.1093/rheumatology/keac260

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Laura Tucker, Alexander Allen, David Chandler, Coziana Ciurtin, Andrew Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak Jadon, Gareth Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, William Tillett, Laura C. Coates^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Need for guideline

PsA is a chronic, inflammatory, musculoskeletal disease affecting approximately one quarter of people with the skin condition psoriasis. PsA is a highly heterogeneous disease, encompassing diverse musculoskeletal manifestations or ‘domains’ resulting from disease activity in different tissues. These include peripheral arthritis, spondylitis (axial inflammation), dactylitis (inflammation of the whole digit) and enthesitis (inflammation where a tendon, ligament or joint capsule insert to the bone). Unlike RA there is a significant variability in clinical presentation of PsA. Individuals with PsA may have different domains involved and drugs have different levels of effectiveness on each domain. The most recent British Society for Rheumatology (BSR) guidelines for the treatment of PsA were published in 2012 [1] and focused specifically on TNF inhibitors as they were the only biologic DMARDs (bDMARDs) available. Since that time, there have been significant advances in therapeutic options available for PsA and drugs with different modes of action are now available, including IL IL17, IL12/23, IL23 p19, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), phosphodiesterase-4 (PDE4) and Janus kinase (JAK) inhibition.

Original language	English
Pages (from-to)	3514-3520
Number of pages	7
Journal	Rheumatology (Oxford, England)
Volume	61
Issue number	9
Early online date	31 May 2022
DOIs	https://doi.org/10.1093/rheumatology/keac260
Publication status	Published - 1 Sept 2022

Bibliographical note

Acknowledgements
We gratefully acknowledge the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the members of their Treatment Recommendations working group who shared extracted data on treatment RCTs for this project.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

Data Availability Statement

All relevant data produced during the guideline development process are presented in the guideline or in the accompanying supplementary material.

Keywords

biologics
dactylitis
enthesitis
guideline
management
PsA
psoriasis
recommendations
targeted synthetic DMARDs
treatment

Access to Document

10.1093/rheumatology/keac260Licence: Unspecified

Cite this

Tucker, L., Allen, A., Chandler, D., Ciurtin, C., Dick, A., Foulkes, A., Gullick, N., Helliwell, P., Jadon, D., Jones, G., Kyle, S., Madhok, V., McHugh, N., Parkinson, A., Raine, T., Siebert, S., Smith, C., Tillett, W., & Coates, L. C. (2022). Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford, England), 61(9), 3514-3520. https://doi.org/10.1093/rheumatology/keac260

Tucker, L, Allen, A, Chandler, D, Ciurtin, C, Dick, A, Foulkes, A, Gullick, N, Helliwell, P, Jadon, D, Jones, G, Kyle, S, Madhok, V, McHugh, N, Parkinson, A, Raine, T, Siebert, S, Smith, C, Tillett, W & Coates, LC 2022, 'Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs', Rheumatology (Oxford, England), vol. 61, no. 9, pp. 3514-3520. https://doi.org/10.1093/rheumatology/keac260

@article{7b2abc3e03ef482ba9c878ff4febe323,

title = "Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs",

abstract = "Need for guidelinePsA is a chronic, inflammatory, musculoskeletal disease affecting approximately one quarter of people with the skin condition psoriasis. PsA is a highly heterogeneous disease, encompassing diverse musculoskeletal manifestations or {\textquoteleft}domains{\textquoteright} resulting from disease activity in different tissues. These include peripheral arthritis, spondylitis (axial inflammation), dactylitis (inflammation of the whole digit) and enthesitis (inflammation where a tendon, ligament or joint capsule insert to the bone). Unlike RA there is a significant variability in clinical presentation of PsA. Individuals with PsA may have different domains involved and drugs have different levels of effectiveness on each domain. The most recent British Society for Rheumatology (BSR) guidelines for the treatment of PsA were published in 2012 [1] and focused specifically on TNF inhibitors as they were the only biologic DMARDs (bDMARDs) available. Since that time, there have been significant advances in therapeutic options available for PsA and drugs with different modes of action are now available, including IL IL17, IL12/23, IL23 p19, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), phosphodiesterase-4 (PDE4) and Janus kinase (JAK) inhibition.",

keywords = "biologics, dactylitis, enthesitis, guideline, management, PsA, psoriasis, recommendations, targeted synthetic DMARDs, treatment",

author = "Laura Tucker and Alexander Allen and David Chandler and Coziana Ciurtin and Andrew Dick and Amy Foulkes and Nicola Gullick and Philip Helliwell and Deepak Jadon and Gareth Jones and Stuart Kyle and Vishnu Madhok and Neil McHugh and Andrew Parkinson and Tim Raine and Stefan Siebert and Catherine Smith and William Tillett and Coates, {Laura C.}",

note = "Acknowledgements We gratefully acknowledge the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the members of their Treatment Recommendations working group who shared extracted data on treatment RCTs for this project. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/rheumatology/keac260",

language = "English",

volume = "61",

pages = "3514--3520",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "OXFORD UNIV PRESS INC",

number = "9",

}

TY - JOUR

T1 - Executive summary

T2 - The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

AU - Tucker, Laura

AU - Allen, Alexander

AU - Chandler, David

AU - Ciurtin, Coziana

AU - Dick, Andrew

AU - Foulkes, Amy

AU - Gullick, Nicola

AU - Helliwell, Philip

AU - Jadon, Deepak

AU - Jones, Gareth

AU - Kyle, Stuart

AU - Madhok, Vishnu

AU - McHugh, Neil

AU - Parkinson, Andrew

AU - Raine, Tim

AU - Siebert, Stefan

AU - Smith, Catherine

AU - Tillett, William

AU - Coates, Laura C.

N1 - Acknowledgements We gratefully acknowledge the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the members of their Treatment Recommendations working group who shared extracted data on treatment RCTs for this project. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Need for guidelinePsA is a chronic, inflammatory, musculoskeletal disease affecting approximately one quarter of people with the skin condition psoriasis. PsA is a highly heterogeneous disease, encompassing diverse musculoskeletal manifestations or ‘domains’ resulting from disease activity in different tissues. These include peripheral arthritis, spondylitis (axial inflammation), dactylitis (inflammation of the whole digit) and enthesitis (inflammation where a tendon, ligament or joint capsule insert to the bone). Unlike RA there is a significant variability in clinical presentation of PsA. Individuals with PsA may have different domains involved and drugs have different levels of effectiveness on each domain. The most recent British Society for Rheumatology (BSR) guidelines for the treatment of PsA were published in 2012 [1] and focused specifically on TNF inhibitors as they were the only biologic DMARDs (bDMARDs) available. Since that time, there have been significant advances in therapeutic options available for PsA and drugs with different modes of action are now available, including IL IL17, IL12/23, IL23 p19, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), phosphodiesterase-4 (PDE4) and Janus kinase (JAK) inhibition.

AB - Need for guidelinePsA is a chronic, inflammatory, musculoskeletal disease affecting approximately one quarter of people with the skin condition psoriasis. PsA is a highly heterogeneous disease, encompassing diverse musculoskeletal manifestations or ‘domains’ resulting from disease activity in different tissues. These include peripheral arthritis, spondylitis (axial inflammation), dactylitis (inflammation of the whole digit) and enthesitis (inflammation where a tendon, ligament or joint capsule insert to the bone). Unlike RA there is a significant variability in clinical presentation of PsA. Individuals with PsA may have different domains involved and drugs have different levels of effectiveness on each domain. The most recent British Society for Rheumatology (BSR) guidelines for the treatment of PsA were published in 2012 [1] and focused specifically on TNF inhibitors as they were the only biologic DMARDs (bDMARDs) available. Since that time, there have been significant advances in therapeutic options available for PsA and drugs with different modes of action are now available, including IL IL17, IL12/23, IL23 p19, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), phosphodiesterase-4 (PDE4) and Janus kinase (JAK) inhibition.

KW - biologics

KW - dactylitis

KW - enthesitis

KW - guideline

KW - management

KW - PsA

KW - psoriasis

KW - recommendations

KW - targeted synthetic DMARDs

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85137138731&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keac260

DO - 10.1093/rheumatology/keac260

M3 - Article

C2 - 35640653

AN - SCOPUS:85137138731

SN - 1462-0324

VL - 61

SP - 3514

EP - 3520

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 9

ER -